They found lower levels of markers of endothelial dysfunction (angiopoietin 2:1 ratio) and inflammation (soluble tumor necrosis factor receptor 1) in COVID-19 compared to patients without COVID-19. This evidence concerns the gene TNFRSF1A and COVID-19.